Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Curr Drug Targets. 2014 Jan;15(1):2–16. doi: 10.2174/1389450114666140106095151

Figure 5. IBR2 inhibits tumor growth by disrupting interaction between RAD51 and BRC repeats.

Figure 5

(A) Structures of IBR compounds (B6 is the negative compound) that disrupt RAD51/BRC repeats interaction. (B) IBR2-RAD51 docking model. IBR2 is shown in ball-and-stick model and colored by hydrophobicity. (Figure adapted from (194))